Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics ofPBFT02 in Adult Subjects with Frontotemporal Dementia (FTD) and GRNMutations
Phase 1
- Conditions
- FRONTOTEMPORAL DEMENTIA (FTD)Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-507724-23-00
- Lead Sponsor
- Passage Bio Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method